X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
STENDRA (avanafil), an oral phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction, provides positive results from its OTC draft label comprehension study for its ED drug demonstrated understanding of the messages therein.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Endo Pharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the STENDRA (avanafil) tablets, to the United States, and is expected to provide both cost savings and increase in gross margin.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 24, 2022
Details:
Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of Petros Pharmaceuticals' men's health platform including Stendra and for working capital and general corporate purposes.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Katalyst Securities LLC
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 30, 2021
Details:
Further expanding the partnership, the companies announce the availability of additional dosages of STENDRA in 50mg, 100mg and 200mg tablets, all of which are now accessible through the Hims platform.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hims & Hers Health, Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 03, 2021
Details:
Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform which includes enhancing the position of STENDRA, and for working capital and general corporate purposes.
Lead Product(s): Avanafil
Therapeutic Area: Endocrinology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Katalyst Securities
Deal Size: $5.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 19, 2021
Details:
Stendra (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
The Company has initiated a Phase 2 study, which is more significant & Label Comprehension Study that will include low health literacy individuals as part of a multi-step process to develop the behavioral study evidence for FDA to evaluate Stendra for possible OTC designation.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2021
Details:
Petros' cornerstone product would be Metuchen's Stendra® for erectile dysfunction. Petros' pipeline would include Metuchen's recently in-licensed product H-100 for Peyronie's disease, and it would include a business development program exploring various men's health products.
Lead Product(s): Avanafil
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurotrope
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
